Complement inhibitors are proteins that help in regulating the complement system in the body. By controlling the cascade reaction, complement inhibitors play a key role in restricting uncontrolled inflammation during autoimmune and inflammatory diseases. Complement inhibitors work by blocking specific proteins in the complement cascade, thereby reducing tissue damage and preventing autoimmune attacks. Eculizumab and ravulizumab are among the widely used complement C5 inhibitors approved for treating paroxysmal nocturnal hemoglobinuria (PNH). The market is also witnessing drugs blocking C1s, C3 and the terminal complement pathway.
The Global Complement Inhibitors Market is estimated to be valued at US$ 6.80 Bn in 2024 and is expected to exhibit a CAGR of 15.% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the Global Complement Inhibitors are Alexion Pharmaceuticals (AstraZeneca), Apellis Pharmaceuticals, Sanofi, CSL Behring, Takeda Pharmaceuticals. Alexion Pharmaceuticals dominates the market with its C5 complement inhibitor drugs.
The increasing prevalence of autoimmune diseases like atypical Hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), Guillain-Barré syndrome (GBS) and paroxysmal nocturnal hemoglobinuria (PNH) is driving the demand for complement inhibitors globally. According to estimates, over 50 million people suffer from some form of autoimmune disease worldwide.
Technological advancements are allowing researchers to identify new complement pathways and develop inhibitors against C1q, C3 and other complement components. This is helping widening the applications of complement inhibitors in treating various inflammatory and autoimmune conditions. Several pipeline drugs are under development that can block early stages of the complement cascade.
Market Trends
Growing preference for recombinant biologics: Biotech companies are focusing on developing recombinant therapies over plasma-derived drugs owing to their increased potency, stability and reduced risks of contamination. This is expected to drive the demand for recombinant complement inhibitors.
Increasing M&A activities: Major players are strategic collaborations and partnerships to strengthen their pipeline drugs. For instance, Alexion acquired Achillion and its C3 complement inhibitor candidates to expand its portfolio.
Market Opportunities
Application in neurological diseases: Complement inhibitors are being evaluated for treating various neurological diseases like stroke, Alzheimer's, multiple sclerosis by inhibiting inflammation in the brain. Successful clinical trials can boost the market growth.
Scope in non-autoimmune renal diseases: Emerging studies indicate the role of complement system in acute kidney injury. Targeting complement can help treat conditions like I/R injury after surgery.
Impact Of COVID-19 On Global Complement Inhibitors Market
The COVID-19 pandemic has greatly impacted the growth of the global complement inhibitors market. During the initial phase of the pandemic in 2020, market growth slowed down significantly as hospital resources were diverted towards treating COVID-19 patients and elective surgeries and procedures were postponed. This led to a reduction in demand for complement inhibitors which are primarily used for treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). However, from 2021 onwards, as vaccination drives progressed and restrictions were gradually lifted, the market has started recovering.
Despite short term disruptions, the long term outlook for the market remains positive due to several factors. There is an increasing incidence of rare diseases like PNH for which complement inhibitors are a frontline treatment option. Advanced therapies like monoclonal antibodies targeting specific components of the complement system are getting developed which is expected to drive usage over the forecast period. Regulatory approvals of newer drugs will also support market growth. Geographical expansion into emerging markets and development of affordable biosimilars are future strategies that can help restore pre-pandemic market levels and achieve higher growth rates in the post COVID era.
In terms of geography, North America currently dominates the Global Complement Inhibitors Market in terms of value. This is attributed to the high healthcare expenditure levels and growing access to novel therapeutics in the region. Europe is the second largest regional market. However, over the next five years, Asia Pacific is projected to emerge as the fastest growing regional market. This is due to rising healthcare investments, growing incidence of target diseases, increasing medical tourism, government initiatives and expansion strategies of leading manufacturers in key Asian countries.
Get more insights on this topic: https://www.trendingwebwire.com/global-complement-inhibitors-market-is-estimated-to-witness-high-growth-owing-to-emerging-complement-targeted-therapies/
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
What Are The Key Data Covered In This Global Complement Inhibitors Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Global Complement Inhibitors Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the Global Complement Inhibitors Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Global Complement Inhibitors Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Global Complement Inhibitors Market vendors
FAQ’s
Q.1 What are the main factors influencing the Global Complement Inhibitors Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Global Complement Inhibitors Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Global Complement Inhibitors Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Comments
0 comment